Endocrine Abstracts (2016) 42 P17 | DOI: 10.1530/endoabs.42.P17

Next generation sequencing panels to predict response to hormonal therapy in prostate cancer

Heini M L Kallio1, Matti Annala1, Anniina Brofeldt1, Reija Hieta1, Kati Kivinummi1, Teuvo Tammela2, Matti Nykter1, Hans G Lilja1, G Steven Bova1 & Tapio Visakorpi1


1Prostate Cancer Research Center, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, Tampere, Finland; 2Prostate Cancer Research Center, Department of Urology, Tampere University Hospital and School of Medicine, University of Tampere, Tampere, Finland.


Prostate cancer (PC) is the most common malignancy and third most common cause of cancer-related death among men in Europe. Although most PCs grow slowly, 20–25% of the patients believed to have organ-confined disease will experience biochemical recurrence already during 5-years of follow-up. The standard treatment against advanced PC is androgen deprivation (ADT). Unfortunately, androgen deprivation treatment eventually fails leading to the emergence of castration resistant PC (CRPC) that is lethal. However, also CRPCs are dependent on androgens. Owing to this understanding, several drugs have recently emerged for the treatment of CRPC including enzalutamide and abiraterone, but approximately 20–40% of patients have no response to these agents. One explanation to this could be the expression of constitutively active androgen receptor splice variants (AR-Vs). The aim of our project is to interrogate all possible AR aberrations in PC and CRPC. We have set up two NGS panels using Agilent’s SureSelect Target Enrichment system allowing detection of all AR transcript variants as well as AR mutations, copy number variations and rearrangements. The assays have been validated with our existing whole-genome sequencing and RNA-seq data. We are now running samples representing hormone-naïve PC, neoadjuvant ADT treated PCs as well as CRPCs. The data will be presented in the meeting.

Presenting author: Heini M.L. Kallio, BioMediTech, University of Tampere, Lääkärinkatu 1, 33520 Tampere, Finland. Email: heini.kallio@uta.fi.

Article tools

My recent searches

No recent searches.